Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Sibanye Stillwater Ltd — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Sibanye Stillwater Ltd trades at $9.44 (market cap $6.99B). The key difference: Sibanye Stillwater Ltd is far larger — about 2.4× Dyne Therapeutics Inc. Common Stock's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Sibanye Stillwater Ltd for 51 Days on average.
| DYN | SBSW | |
|---|---|---|
Market Cap | $2.86B | $6.99B |
Volume | 3,341,579 | 3,905,859 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $21.12 |
52-Week Low | $14.60 | $8.00 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $2.18B | $7.89B |
Dividend Yield | — | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SBSW trades at $9.42, down 4.75% on the day, amid a bearish technical signal. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though profitability is projected to improve significantly in 2026. Analyst consensus is a Moderate Buy with a $14.25 price target. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a surge in operating cash flow, signaling a potential turnaround.
The outlook for SBSW hinges on executing its growth roadmap and capital discipline. Investment opportunities include attractive valuation multiples and projected earnings recovery, but risks persist from commodity price volatility, high debt levels, and operational challenges in South African mining. The stock offers value if management delivers on its 2027-2028 targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
